Global Biodefense 麻豆原创 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Region: Trend Forecast and Growth Opportunity

Publication ID:

GRM0620001

Publication Date:

June 26, 2020

Pages:

165

Publisher:

Grace 麻豆原创 Data

Countries:

Global [1]

USD 2,980.00

Defense & Security [2]

Defence [3]

Industry & Manufacturing [4]

Description:

Global biodefense market will reach $15.85 billion by 2030, growing by 6.2% annually over 2020-2030 owing to the rising need for military and civilian vaccines and equipment against diseases including COVID-19 pandemic.
Highlighted with 84 tables and 73 figures, this 165-page report 鈥淕lobal Biodefense 麻豆原创 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Region: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire global biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Region.
Based on Product, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Vaccines
鈥� Anthrax
鈥� Smallpox
鈥� Botulism
鈥� Nuclear/Radiation
鈥� E-Bola
鈥� Zika
鈥� Other Vaccines
Biothreat Detection Devices
鈥� Detectors/Triggering Devices
鈥� Assays and Reagents
鈥� Samplers
鈥� Identifiers
Antibiotics
Masks
Other Products
Based on Sales Channel, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Online Sales
鈥� Offline Sales
Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Military
鈥� Civilian
Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
鈥� Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
鈥� North America (U.S., Canada, and Mexico)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� RoW (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product, Sales Channel, Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global biodefense market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc.
Alexeter Technologies LLC
Alnylam Pharmaceuticals, Inc.
Altimmune, Inc.
Bavarian Nordic AS
BioFactura, Inc.
Cleveland Biolabs, Inc.
Dynavax Technologies Inc
Dynport Vaccine Company LLC (DVC)
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc
General Dynamics Corp.
GlaxoSmithKline Plc
Ichor Medical Systems
Mediimmune (AstraZeneca)
Nanotherapeutics, Inc.
Ology Bioscience
PathSensors Inc
Pluristem Therapeutics
Sanofi Pasteur Ltd.
SIGA Technologies, Inc.
Soligenix, Inc.
Xoma Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of 麻豆原创 Research Methodology 12
1.2.2 麻豆原创 Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 15
1.2.6 麻豆原创 Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.2 Major Growth Drivers 21
2.3 麻豆原创 Restraints and Challenges 24
2.4 Emerging Opportunities and 麻豆原创 Trends 27
2.5 Porter鈥檚 Fiver Forces Analysis 31
3 Segmentation of Global 麻豆原创 by Product 35
3.1 麻豆原创 Overview by Product 35
3.2 Vaccines 37
3.2.1 Anthrax 40
3.2.2 Smallpox 41
3.2.3 Botulism 42
3.2.4 Nuclear/Radiation 43
3.2.5 E-Bola 44
3.2.6 Zika 45
3.2.7 Other Vaccines 46
3.3 Biothreat Detection Devices 47
3.4 Antibiotics 49
3.5 Masks 50
3.6 Other Products 51
4 Segmentation of Global 麻豆原创 by Sales Channel 52
4.1 麻豆原创 Overview by Sales Channel 52
4.2 Online Sales 54
4.3 Offline Sales 55
5 Segmentation of Global 麻豆原创 by Application 56
5.1 麻豆原创 Overview by Application 56
5.2 Military 58
5.3 Civilian 59
6 Segmentation of Global 麻豆原创 by Region 60
6.1 Geographic 麻豆原创 Overview 2019-2030 60
6.2 North America 麻豆原创 2019-2030 by Country 64
6.2.1 Overview of North America 麻豆原创 64
6.2.2 U.S. 68
6.2.3 Canada 72
6.2.4 Mexico 74
6.3 European 麻豆原创 2019-2030 by Country 76
6.3.1 Overview of European 麻豆原创 76
6.3.2 Germany 80
6.3.3 UK 82
6.3.4 France 84
6.3.5 Spain 86
6.3.6 Italy 88
6.3.7 Russia 90
6.3.8 Rest of European 麻豆原创 92
6.4 Asia-Pacific 麻豆原创 2019-2030 by Country 94
6.4.1 Overview of Asia-Pacific 麻豆原创 94
6.4.2 Japan 98
6.4.3 China 101
6.4.4 Australia 103
6.4.5 India 105
6.4.6 South Korea 107
6.4.7 Rest of APAC Region 109
6.5 South America 麻豆原创 2019-2030 by Country 111
6.5.1 Argentina 114
6.5.2 Brazil 116
6.5.3 Chile 118
6.5.4 Rest of South America 麻豆原创 120
6.6 Rest of World 麻豆原创 2019-2030 by Country 121
6.6.1 UAE 124
6.6.2 Saudi Arabia 126
6.6.3 South Africa 128
6.6.4 Other National 麻豆原创s 130
7 Competitive Landscape 131
7.1 Overview of Key Vendors 131
7.2 New Product Launch, Partnership, Investment, and M&A 134
7.3 Company Profiles 135
Achaogen, Inc. 135
Alexeter Technologies LLC 137
Alnylam Pharmaceuticals, Inc. 138
Altimmune, Inc. 139
Bavarian Nordic AS 140
BioFactura, Inc. 141
Cleveland Biolabs, Inc. 142
Dynavax Technologies Inc 143
Dynport Vaccine Company LLC (DVC) 144
Elusys Therapeutics, Inc. 145
Emergent BioSolutions Inc 146
General Dynamics Corp. 147
GlaxoSmithKline Plc 148
Ichor Medical Systems 149
Mediimmune (AstraZeneca) 150
Nanotherapeutics, Inc. 151
Ology Bioscience 152
PathSensors Inc 153
Pluristem Therapeutics 154
Sanofi Pasteur Ltd. 155
SIGA Technologies, Inc. 156
Soligenix, Inc. 157
Xoma Corporation 158
8 Investing in Global 麻豆原创: Risk Assessment and Management 159
8.1 Risk Evaluation of Global 麻豆原创 159
8.2 Critical Success Factors (CSFs) 162
Related Reports and Products 165

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc.
Alexeter Technologies LLC
Alnylam Pharmaceuticals, Inc.
Altimmune, Inc.
Bavarian Nordic AS
BioFactura, Inc.
Cleveland Biolabs, Inc.
Dynavax Technologies Inc
Dynport Vaccine Company LLC (DVC)
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc
General Dynamics Corp.
GlaxoSmithKline Plc
Ichor Medical Systems
Mediimmune (AstraZeneca)
Nanotherapeutics, Inc.
Ology Bioscience
PathSensors Inc
Pluristem Therapeutics
Sanofi Pasteur Ltd.
SIGA Technologies, Inc.
Soligenix, Inc.
Xoma Corporation

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.